GeoVax to Report Q3 2025 Financial Results and Provide Business Update on November 13

GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

The upcoming financial report and corporate update hold significance for investors and the healthcare sector as GeoVax advances multiple clinical programs targeting critical medical needs. The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials are evaluating the vaccine as a primary vaccine for immunocompromised patients, including those with hematologic cancers, as a booster vaccine in patients with chronic lymphocytic leukemia, and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.

In oncology, GeoVax's lead clinical program involves Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox and, based on recent European Medicines Agency regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials.

To access the live conference call, participants may register in advance through the company's registration portal at https://edge.media-server.com/mmc/p/u86rmdmb/. The live audio webcast of the call will be available via the Events & Presentations section of the company's Investor Relations website at https://www.geovax.com/investors. An archive of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for at least 90 days.

The financial results and business update come at a crucial time for vaccine development, particularly as the healthcare industry continues to address the needs of immunocompromised populations who may not respond adequately to current COVID-19 vaccines. GeoVax's progress in developing targeted vaccines for these vulnerable patient groups could significantly impact public health outcomes and fill important gaps in current vaccination strategies. The company's oncology programs also represent important advancements in cancer treatment, particularly for patients with advanced head and neck cancers where new therapeutic options are urgently needed.

GeoVax maintains a strong intellectual property portfolio supporting its technologies and product candidates, holding worldwide rights for its technologies and products. The company's forward-looking statements emphasize the potential of its vaccine platforms but also acknowledge various risk factors that could affect development timelines and regulatory approvals. These include uncertainties around clinical trial results, manufacturing capabilities, regulatory pathways, and competitive landscape developments.